Key takeaways
- Each example reports its own population; a total across four studies chosen as examples would describe the selection, not peptide research, so this page gives none.
- Three of the studies gave a study peptide to their participants; the fourth measured naturally occurring MOTS-c in 10 men without giving them the peptide.
- One sponsor-submitted record lists ages 18–45 and exclusions for pregnancy, breastfeeding, and some people subject to formal anti-doping testing. Those are listed criteria, not verified enrollment.
- A study that includes women and men does not necessarily tell you whether their results differed.
01How many women and men were in these studies?
If you searched “peptides for women”, the question a study can answer is narrower: whom it enrolled, and whether it compared women and men. We chose four published human studies as examples; other studies of the same compounds exist and are not counted here. The table uses the groups the authors reported and says so where the source we could read gives no figure. It is not a census of peptide research or a ranking for women or men.
| Human study | Participants | Women | Men | Age | Study design and measures |
|---|---|---|---|---|---|
| BPC-157 · Lee, Walker and Ayadi (2024) [1] | 12 | 12 | 0 | 39–76 years | T2, pilot without a control group; participant questionnaire. The study did not test material sold online. |
| BPC-157 · Lee and Burgess (2025) [2] | 2 | 1 | 1 | Woman: 68; man: 58 | T2, pilot without a control group; measures included blood tests and vital signs. Both people had received BPC-157 before. The study did not test material sold online. |
| GHK-Cu · Bo et al. (2026) [3, 4] | 18 | Not in the abstract | Not in the abstract | 18–40 in the abstract | T1, randomized within-person comparison with placebo; measures included eyebrow hair count and diameter. The study tested one specific formulation. |
| Natural MOTS-c levels · Reynolds et al. (2021) [5] | 10 | 0 | 10 | Mean age 24.5 years | T2, human exercise study; researchers measured naturally occurring MOTS-c in blood and muscle. They did not give the peptide to the men. |
We give no total. These four studies were chosen as examples, asked different questions, and one gave no one a peptide, so a sum would describe the selection, not peptide research. A table of who took part also does not tell you whether women and men responded differently.
02What did the sources exclude by pregnancy, sport, and age?
Eligibility tells you who a study was designed to include, not who enrolled. The 2026 BPC-157 hamstring listing on ClinicalTrials.gov (NCT07437547) is a sponsor-submitted record. We use it here to describe the listed criteria, not as confirmation that anyone enrolled or received the peptide. It is not one of the four examples. [6, 7]
- Pregnancy and breastfeeding. The hamstring listing excludes people who are pregnant or breastfeeding. It also lists a negative pregnancy test at baseline for participants who could become pregnant. These are study criteria, not evidence about pregnancy or breastfeeding. [6]
- Formal anti-doping testing. The same listing allows organized recreational sport to meet its activity criterion. It separately excludes people “Currently subject to a formal anti-doping testing program” where “use of an investigational peptide could create a regulatory conflict”, unless the relevant authority explicitly approves. It does not list a blanket exclusion for everyone who plays sport. [6]
- Age. The hamstring listing gives an eligible range of 18–45 years. The GHK-Cu eyebrow study’s abstract describes 18 healthy participants aged 18–40; we could not open the thesis that reports their actual ages. The older ages in the 2024 BPC-157 pilot describe that group, not an age rule for another study. [1, 3, 4, 6]
Sport rules are separate from study eligibility. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 in section S0 and prohibits it at all times, in and out of competition. A line in a registry entry does not change that rule. See peptides and anti-doping for how to read the list. [8]
03How can you read a study’s participant count?
Look for a participant characteristics table or a results section. An enrollment target is not a head count. A field marked “All” under eligible sexes does not tell you how many women or men joined. [6, 9]
In the Reynolds study, the men exercised and researchers measured a peptide already in their bodies. That is human evidence about a measured level, not a study of people receiving MOTS-c. [5]
A table showing women and men tells you who was represented. To answer whether they responded differently, look for a direct analysis that compares the groups, not just a result reported for everyone together. See our evidence grades for how study design shapes the conclusions.
04What we don’t know
These examples do not establish whether the same findings would apply during pregnancy or breastfeeding, to children, or to athletes subject to formal testing. Nor can you compare the women in one study with the men in another and call the difference a sex effect. The studies asked different questions, used different measures, and did not all administer a peptide. [1–6]
If your next question is what the human evidence can tell you about risk, read how to assess peptide safety. If your question is what a supplier’s paperwork actually verifies, see how to vet a peptide supplier. A participant table and a lab report answer different questions.
This is a plain-English summary of public studies and documents, checked on 21 November 2026. Not medical or legal advice.